AstraZeneca Cancer Drug Selumetinib Fails in Lung Trial

  • Medicine didn’t help patients live longer or without disease
  • Setback comes days after Opdivo from Bristol-Myers disappoints

AstraZeneca Plc’s experimental medicine selumetinib failed to keep a common form of lung cancer at bay in an advanced clinical test, making it the second drugmaker to report a setback in battling tumors of the lung this month.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.